Exosome Formulation Development
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
At Creative BioMart Microbe, we develop application-driven formulations for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), probiotic-derived exosomes, fungal EVs, and phage-derived vesicles. Our platform covers five distinct formulation types—liquid buffers, lyophilized powders, thermoresponsive hydrogels, enteric-coated microspheres, and inhalation-compatible solutions—each optimized for the unique lipidome, proteome, and immunogenic profile of microbial vesicles rather than adapted from mammalian exosome templates.
Every formulation is validated through integrated stability profiling and post-formulation functional testing to ensure that excipients and processing preserve therapeutic activity. Clients receive regulatory-ready documentation suitable for IND-enabling CMC packages, cosmetic raw-material registrations, and vaccine adjuvant filings. If your program would benefit from coordinated upstream development or integrated drug-loading strategies, we can align formulation design with strain engineering, fermentation optimization, isolation, and cargo-loading workflows. Contact us to discuss your current stage and how we can support your next steps.
Figure 1. Schematic overview of the integrated exosome formulation platform, spanning liquid formulation design, lyophilization cycle development, hydrogel and sustained-release matrix engineering, enteric and mucosal coating optimization, inhalation and nasal spray formulation, aseptic fill-finish, and integrated QC release with real-time stability monitoring.
Services
Service Workflow
Service Details
Liquid Formulation Development
We develop buffered liquid formulations optimized for colloidal stability of microbial vesicles at 2–8 °C. Buffer systems are selected and titrated for pH, ionic strength, and osmolality to prevent aggregation, membrane fusion, and payload leakage. Surfactant and stabilizer profiles are screened to maintain particle size distribution and zeta potential within specification over the intended shelf life. Each formulation is validated for post-storage bioactivity to confirm that buffer components do not compromise therapeutic function.
Lyophilized Formulation Development
We design freeze-dried formulations that eliminate cold-chain dependence and extend shelf life. A systematic cryoprotectant screening matrix evaluates trehalose, mannitol, sucrose, methionine, PEG derivatives, and proprietary blends based on vesicle membrane composition. Lyophilization cycle parameters—freezing rate, primary drying temperature and duration, secondary drying hold time, and chamber pressure—are optimized to preserve spherical morphology, prevent ice-crystal damage, and achieve rapid reconstitution. Final products are evaluated for cake appearance, reconstitution time, particle recovery rate, and post-lyophilization potency retention.
Hydrogel & Sustained-Release Formulation Development
We engineer thermoresponsive and pH-responsive hydrogel matrices that embed mEVs for localized, sustained release at lesion sites. Gelation kinetics, mesh pore size, and vesicle distribution uniformity are tuned to control burst-release profiles and achieve zero-order, first-order, Higuchi, Korsmeyer-Peppas, or Peppas-Sahlin release kinetics. Composite microsphere formulations with biodegradable polymers are developed for depot-release applications. Release profiles are validated under simulated physiological conditions with pharmacokinetic curve fitting.
Enteric & Mucosal Formulation Development
We develop enteric-coated microspheres and acid-resistant composites that protect microbial exosomes from gastric degradation and enable intestinal targeting. Coating polymers, plasticizer ratios, and curing conditions are optimized for dissolution pH threshold and mucoadhesive properties. GI-stability is validated by simulated digestion models, and barrier-repair or immunomodulatory potency is confirmed post-passage through gastric and intestinal compartments.
Inhalation & Nasal Spray Formulation Development
We engineer nebulizer-compatible liquids and nasal spray solutions that maintain vesicle integrity through aerosolization stress. Droplet size distribution, osmolality, and viscosity are optimized for pulmonary deposition or nasal mucosal absorption. Spray-dried and freeze-dried powder formulations are developed for dry powder inhalers, with particle engineering to achieve optimal aerodynamic diameter and high reconstitution yield. Stability under aerosolization shear stress is validated by particle size and bioactivity retention assays.
Aseptic Fill-Finish Process Development
We provide sterile fill-finish process development for vials, pre-filled syringes, and cartridges. Fill volume accuracy, stopper seating, capping torque, and container-closure integrity are validated. Sterility assurance protocols align with USP <71> and Ph. Eur. 2.6.1. Endotoxin control, particulate monitoring, and visual inspection are integrated into batch release documentation suitable for IND-enabling CMC packages.
Service Specifications & QC Standards
Formulation & Stability Capability
- Supported formulation platforms: liquid buffer, lyophilized powder, thermoresponsive hydrogel composite, enteric-coated microspheres, nasal spray solution, nebulizer-ready liquid, spray-dried powder for dry powder inhalers.
- Stress testing panel: thermal (25 °C/60% RH, 40 °C/75% RH), photostability (ICH Q1B Option 1 & 2), mechanical agitation, osmotic shock, acid/base hydrolysis, oxidation, and repeated freeze-thaw.
- Cryoprotectant library: trehalose, mannitol, sucrose, methionine, PEG 400/3350, dextran, and proprietary blends.
- Release kinetics modeling: zero-order, first-order, Higuchi, Korsmeyer-Peppas, and Peppas-Sahlin models for hydrogel and microsphere formulations.
- Fill-finish formats: 2R–10R glass vials, pre-filled syringes (1 mL–5 mL), and cartridges.
- QC alignment: MISEV2023 guidelines; GxP-compliant assay formats available for regulatory submissions.
Typical Data Range
- Post-lyophilization particle size shift: <15% versus native vesicles.
- Lyophilization particle recovery rate: >85%.
- Liquid formulation stability at 2–8 °C: ≥3 months (particle size, zeta potential, and potency retention).
- Lyophilized formulation stability at –20 °C: ≥24 months.
- Lyophilized formulation stability at 2–8 °C: ≥12 months.
- Lyophilized formulation stability at 25 °C: ≥1–3 months (pilot data for cold-chain reduction).
- Hydrogel release half-life in simulated physiological fluid: 2–12 hours depending on matrix composition.
- Enteric coating dissolution pH threshold: ≥5.5 (gastric resistance) with complete release within 60 minutes at pH 6.8.
- Inhalation solution droplet size (MMAD): 1–5 μm for pulmonary deposition.
- Post-stress bioactivity retention: >80% of baseline.
- Endotoxin level for in vivo-grade samples: <0.5 EU/mL.
- Sterility: compliant with USP <71> / Ph. Eur. 2.6.1.
- Fill volume accuracy: ±5% of target.
Turnaround Time
| Project Type |
Timeline |
| Liquid formulation development & optimization |
2–4 weeks |
| Lyophilized formulation development & cycle optimization |
3–5 weeks |
| Hydrogel & sustained-release formulation development |
3–5 weeks |
| Enteric & mucosal formulation development |
3–5 weeks |
| Inhalation & nasal spray formulation development |
3–5 weeks |
| Aseptic fill-finish process development |
2–3 weeks |
| Stability monitoring (1-/3-/6-month timepoints) |
1–6 months |
| Integrated QC package (release + characterization) |
2–3 weeks |
| Complete formulation-to-release project |
8–16 weeks |
Timeline may vary based on formulation complexity, vesicle source, and assay customization.
Deliverables
- Experimental protocols and SOP summaries.
- Raw data files (NTA datasets, TEM imaging, lyophilization cycle logs, release kinetics curves, stability trend charts, fill-finish batch records).
- Processed analytical reports with statistical analysis and publication-ready charts.
- Certificate of Analysis (CoA) per batch.
- Liquid formulation report (buffer composition, pH/osmolality, colloidal stability data).
- Lyophilization process development report (cycle parameters, cake appearance scoring, reconstitution data).
- Hydrogel formulation report (gelation kinetics, mesh pore size, release curve fitting, mechanism interpretation).
- Enteric coating development report (dissolution pH threshold, mucoadhesive properties, GI-stability validation).
- Inhalation formulation report (droplet size distribution, aerodynamic particle size, nebulizer compatibility validation).
- Fill-finish batch record and container-closure integrity report.
- Methodology summary and instrument calibration records.
- Optional CQA documentation package for IND-enabling studies or cosmetic raw-material registration.
Quality Control
- Batch-level instrument calibration with certified positive and negative controls.
- Inter-batch consistency assessment (particle size CV <10%, potency CV <15%, fill volume CV <5%).
- MISEV2023 compliance checklist for all formulation and stability assays.
- Contaminant screening for residual cryoprotectant, organic solvent, unencapsulated free drug, detergent, hydrogel monomer, and enteric coating polymer.
- Endotoxin monitoring for all in vivo-grade samples.
- Sterility, mycoplasma, and microbial limit testing per USP / Ph. Eur.
- Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.
Samples
Sample Submission Requirements
| Required Information |
Optional Information |
Not Accepted |
- Sample type (purified microbial exosomes, crude fermentation supernatants, pre-engineered mEVs, lyophilized exosomes, conditioned media)
- Estimated particle concentration (NTA or equivalent) and total protein yield
- Buffer composition, pH, and osmolality of current storage buffer
- Current storage temperature and duration
- Sample volume (≥1 mL recommended for single-platform development; ≥5 mL for multi-platform screening)
- Presence of residual detergents, solvents, or excipients from upstream processing
- Endotoxin level (for in vivo-grade formulation projects)
- Desired functional endpoints for post-formulation validation
|
- Prior isolation method (TFF, SEC, ultrafiltration, density gradient, or other)
- Target application (research, CMC, regulatory filing, cosmetic-grade, food-grade, vaccine adjuvant)
- Target route of administration (IV, oral, topical, inhalation, intranasal)
- Preferred formulation platform (liquid, lyophilized, hydrogel, enteric, inhalation)
- Target shelf-life claim and acceptable storage temperature range
- Fill-finish format preference (vial size, syringe, cartridge)
- Regulatory documentation requirements (CoA, SOP, CQA package, stability protocol)
- Control sample requirements (untreated, vehicle-only, empty vesicle, or competitor benchmark)
|
- Samples subjected to more than three freeze-thaw cycles
- Samples with unidentified strain origin or undocumented culture conditions
- Severely degraded, aggregated, or contaminated preparations
- Samples preserved with fixatives, antimicrobial agents, or non-sterile buffers
- Samples shipped at inadequate temperature or with compromised cold-chain documentation
- Samples in buffers with extreme pH (<5.5 or >8.5) incompatible with formulation development
|
Recommended Sample Quantity by Application
| Application |
Recommended Amount |
Rationale |
| Single-platform liquid formulation development |
≥1 mg total protein or ≥1×1010 particles |
Sufficient for buffer screening, pH/osmolality titration, and 4-week stability monitoring |
| Single-platform lyophilized formulation development |
≥2 mg total protein or ≥2×1010 particles |
Requires additional material for cryoprotectant matrix screening and cycle optimization |
| Multi-platform comparative screening (2–3 platforms) |
≥3 mg total protein or ≥3×1010 particles |
Enables parallel evaluation of formulation candidates with adequate replication |
| Hydrogel & sustained-release formulation development |
≥1.5 mg total protein |
Material partitioned between matrix preparation, gelation kinetics, and release profiling |
| Enteric & mucosal formulation development |
≥1.5 mg total protein |
Coating process consumes additional material; GI-stability validation requires replicate aliquots |
| Inhalation & nasal spray formulation development |
≥1.5 mg total protein |
Aerosolization stress testing and droplet size analysis require dedicated sample sets |
| Aseptic fill-finish process development |
≥2 mg total protein |
Engineering runs, fill-volume accuracy validation, and container-closure integrity testing |
| Accelerated stability study (full ICH panel) |
≥2 mg total protein |
Multiple stress conditions (thermal, photostability, mechanical, freeze-thaw) run in parallel |
| Long-term real-time stability monitoring |
≥4 mg total protein (aliquoted per timepoint) |
1/3/6/9/12-month timepoints with backup aliquots for retest |
| In vitro functional validation post-formulation |
≥500 μg total protein |
Cell uptake, cytokine modulation, or barrier-repair potency confirmation |
| In vivo pilot studies (formulated mEVs) |
≥3–5 mg total protein |
Animal dosing, biodistribution, and toxicity assessment with formulation-specific controls |
Storage & Shipping
Ship frozen at –80 °C on dry ice. Store at –80 °C upon receipt. Avoid repeated thawing. Recommended buffer: sterile PBS, pH 7.4, endotoxin-free, with documented osmolality (280–320 mOsm/kg preferred). For samples already in non-PBS buffers, provide complete buffer formulation with concentration of all components. Lyophilized samples should be shipped with desiccant in amber vials, protected from light and moisture, with residual moisture content documentation if available. Liquid samples in organic solvents or detergent-containing buffers must be flagged prior to shipment for compatibility assessment.
Our Advantages
- Microbial EV Formulation Specialization: Deep expertise in bacterial OMVs, probiotic EVs, and fungal vesicles. Every buffer system, cryoprotectant matrix, and lyophilization cycle is optimized for microbial membrane composition, not adapted from mammalian templates.
- Five Distinct Formulation Platforms: Liquid, lyophilized, hydrogel, enteric, and inhalation formulations are each developed as dedicated platforms with route-specific validation protocols rather than as variations of a single generic buffer system.
- Lyophilization-First Platform: Proprietary cryoprotectant screening matrices and cycle development protocols achieve >85% particle recovery and room-temperature pilot stability, reducing global cold-chain dependence.
- Application-Driven Formulation Design: Each platform is optimized for specific routes of administration and disease indications—injectable liquids for systemic delivery, enteric microspheres for GI targeting, hydrogels for wound retention, and inhalation solutions for pulmonary or nose-to-brain applications.
- Regulatory-Ready Documentation: Deliverables support CMC packages, IND-enabling stability data, cosmetic raw-material registration, and food-grade safety filings with ICH-aligned protocols and GxP-compliant formats.
- Closed-Loop Formulation-to-Function Validation: Formulated vesicles are not released after physical characterization alone. We validate post-formulation bioactivity—including cell uptake, cytokine modulation, barrier-repair potency, and release kinetics—to ensure that excipients and processing preserve therapeutic function.
Applications
Injectable Formulation for Systemic Delivery
Liquid or lyophilized formulations optimized for intravenous or subcutaneous administration, with colloidal stability, low immunogenicity, and targeted retention in circulation.
GI-Targeted Enteric Formulation
Enteric-coated microspheres and acid-resistant composites for oral delivery of probiotic exosomes and OMVs to the intestinal epithelium, validated for GI stability and mucosal adhesion.
Topical & Wound-Healing Hydrogel Formulation
Thermoresponsive and pH-responsive hydrogel matrices that embed mEVs for localized, sustained release at cutaneous or mucosal lesion sites, promoting tissue repair and inflammation resolution.
Inhalation & Nasal Spray Formulation
Nebulizer-compatible liquids and nasal spray solutions engineered to maintain vesicle integrity through aerosolization, enabling pulmonary deposition and potential olfactory-to-CNS transport.
Lyophilized Formulation for Global Distribution
Freeze-dried powders with validated ambient-temperature stability for vaccine adjuvants, cosmetic actives, and clinical supplies that must ship without continuous cold chain.
Cosmetic & Dermal Delivery Systems
Skin-penetration-optimized liquid and lyophilized formulations for anti-inflammatory, barrier-repair, and anti-aging applications, with cosmetic raw-material compliance documentation.
Vaccine Adjuvant Formulation
Stabilized OMV and bacterial exosome formulations that retain potent immunostimulatory activity while minimizing reactogenicity, suitable for preclinical and clinical vaccine development.
Case Study
Case Study 1: Hybrid Membrane-Coated Lipid Nanoparticle Formulation for Dual-Targeted Antibiotic Delivery
Researchers developed neutrophil-bacterial hybrid membrane vesicle (HMV)-coated biofunctional lipid nanoparticles (LNP@HMVs) by fusing E. coli-derived outer membrane vesicles with HL-60 neutrophil membrane vesicles through sonication and extrusion. FRET assays confirmed successful membrane fusion at 1:1 protein weight ratio. The resulting LNP@HMVs exhibited spherical core-shell morphology by TEM, increased hydrodynamic size versus uncoated LNPs, and inherited membrane proteins from both parent vesicles. Norfloxacin-loaded LNP@HMVs demonstrated sustained release kinetics with approximately 25% and 50% drug release at 1 and 36 hours, respectively. The hybrid membrane coating conferred dual-targeting capacity to inflammatory endothelial cells via neutrophil β2 integrin and to homologous Gram-negative bacteria via OMV membrane homology, achieving enhanced antibacterial efficacy against planktonic bacteria and biofilms in vitro and potent therapeutic outcomes in systemic and lung infection models in vivo.
Figure 2. Characterization of hybrid membrane vesicles and formulated lipid nanoparticles. (Peng, et al. 2024)
FAQs
Q: What formulation platforms do you offer for microbial exosomes?
A: We operate five formulation platforms: liquid buffer formulations, lyophilized powders, thermoresponsive hydrogel composites, enteric-coated microspheres, and inhalation-compatible solutions including nasal sprays and nebulizer-ready liquids. Platform selection is driven by target route of administration, required shelf-life, and stability profile of the specific vesicle source.
Q: How do you optimize lyophilization cycles for microbial vesicles?
A: We screen cryoprotectant matrices—including trehalose, mannitol, methionine, sucrose, and PEG derivatives—and optimize freezing rate, primary drying temperature and duration, secondary drying hold time, and chamber pressure. Final cycles are validated for cake appearance, reconstitution time, particle recovery, and post-lyophilization bioactivity retention.
Q: What stability studies are included in your standard package?
A: Standard packages include accelerated stability (ICH Q1A), long-term real-time monitoring, forced degradation (thermal, photostability, mechanical agitation, pH stress, osmotic shock, and freeze-thaw cycling), and in-use stability. Custom stress profiles and timepoint schedules are available upon request.
Q: Can you support aseptic fill-finish for clinical-grade exosomes?
A: Yes. We develop fill-finish processes for vials, pre-filled syringes, and cartridges with sterility assurance per USP <71> and Ph. Eur. 2.6.1, endotoxin control, particulate monitoring, and container-closure integrity validation. Batch records and CoAs support IND-enabling CMC packages.
Q: How is each formulation platform validated?
A: Every platform undergoes route-specific validation. Liquid formulations are tested for colloidal stability and post-storage bioactivity. Lyophilized products are evaluated for cake appearance, reconstitution time, particle recovery, and ambient-temperature pilot stability. Hydrogels are profiled for gelation kinetics, mesh pore size, and release curve fitting. Enteric coatings are validated by dissolution pH threshold and GI-stability simulation. Inhalation solutions are tested for droplet size distribution and aerosolization stress resistance.
Q: What is the typical shelf life of your formulated microbial exosomes?
A: Lyophilized formulations typically achieve ≥24 months at –20 °C, ≥12 months at 2–8 °C, and 1–3 months of pilot stability at 25 °C—eliminating dry-ice cold-chain dependency. Liquid formulations generally maintain stability for 1–3 months at 2–8 °C, depending on vesicle source, buffer composition, and presence of stabilizing excipients.
Q: Do you develop formulations for non-invasive routes such as oral or inhalation?
A: Yes. Our enteric platform develops coated microspheres for oral and GI-targeted delivery. Our inhalation platform develops nasal sprays for systemic or nose-to-brain transport, and nebulizer-ready solutions for pulmonary deposition. Each route-specific formulation is validated for stability under simulated physiological and aerosolization stress.
Q: What documentation do you provide for regulatory submissions?
A: We provide CoA per batch, ICH-aligned stability reports, lyophilization process development reports, hydrogel formulation reports, enteric coating development reports, inhalation formulation reports, fill-finish batch records, SOP summaries, method validation records, and optional GxP-aligned CQA documentation suitable for FDA IND submissions, EMA IMPD filings, and cosmetic raw-material registrations.
Q: How do I choose between liquid and lyophilized formulation?
A: Liquid formulations are preferred for short-term research use, immediate administration, and applications requiring rapid reconstitution. Lyophilized formulations are recommended for long-term storage, global distribution without continuous cold chain, clinical supply continuity, and shelf-life extension.
Q: What is the typical turnaround for a complete formulation project?
A: Standalone platform development requires 2–5 weeks. Integrated formulation-to-release projects typically require 8–16 weeks. Long-term stability monitoring extends beyond this based on ICH-mandated timepoints (1, 3, 6, 9, 12, 18, 24, 36 months).
References:
- Peng, X., et al. (2024). Biofunctional lipid nanoparticles for precision treatment and prophylaxis of bacterial infections. Science advances, 10(14), eadk9754.
